Pharma Update

Neuroscience pipeline Industry leading portfolio differentiated on targets and platform technologies M Ph I (5 NMEs) Ph II (10 NMEs) prasinezumab Parkinson's Ph III (1 NME, 5AI) Launched (4) RG7935 rugonersen RG6168 RG6091 Angelman syndrome Enspryng gMG RG1594 RD RD Ocrevus Multiple Sclerosis semorinemab RG6100 Alzheimer's RG6168 Enspryng RG6035 brain shuttle CD20 Multiple Sclerosis MOG-AD RD RG6168 bepranemab* Enspryng NMOSD RG6100 RD Alzheimer's RG6168 Enspryng AIE RD RG6182 MAGLI Multiple Sclerosis trontinemab RG6102 Alzheimer's RG7916 fenebrutinib Evrysdi SMA type 1/2/3 RG7845 RD undisclosed RG6289 Alzheimer's MA Multiple Sclerosis tominersen RG6042 Huntington's RG1594 RG6237 + GYM329+ Evrysdi Ocrevus high dose Multiple Sclerosis RG6356 Elevidys DMD RD RG7916 SMA RD RG6163 undisclosed psychiatric disorders RG1594 GYM329 Ocrevus SC Multiple Sclerosis RG6237 FSHD RD Neuro-immunologic disorders ralmitaront RG7906 Small molecule Antibody Gene therapy Brain shuttle Schizophrenia مه RG7816 alogabat RG7314 Autism spectrum disorder balovaptan PTSD Neuro-degenerative disorders Neuro-developmental disorders Neuro-muscular disorders Psychiatric disorders Locked nucleic acid / antisense RG1662 basmisanil Dup 15q syndrome RD Upcoming readouts Ph III (EMBARK) Elevidys (delandistrogene moxeparvovec) in DMD data expected in Q4 2023 Ph III (LUMINESCE) Enspryng in gMG data expected in H1 2024 FDA approval RD RD Rare disease NME=new molecular entity; Al-additional indication; NMOSD=neuromyelitis optica spectrum disorders; DMD=Duchenne muscular dystrophy; gMG=generalised myasthenia gravis; SMA=spinal muscular atrophy; FSHD=facioscapulohumeral muscular dystrophy; PTSD-post-traumatic stress disorder; MOG-AD=myelin oligodendrocyte glycoprotein antibody-associated disease; AIE-autoimmune encephalitis; MAGL-monoacylglycerol lipase; *Bepranemab partnered with UCB, studies are currently run by UCB Roche 100

View entire presentation